BioAffinity Aims to Revive Cancer Diagnostic in San Antonio
Summary
After bioAffinity collects the sputum—basically phlegm that’s coughed up from the lungs—it adds its diagnostic agent, called CyPath, which is a type of molecule known as a porphyrin.The researcher and surgeon at Meridian who is working with bioAffinity, Thomas Bauer, was also the lead investigator of the study the company completed in 2011.Given her family’s history with cancer—besides her brother, Zannes’s mother fought breast cancer and her father died from lung cancer—Zannes says she decided to stay with the business, which was traded publicly over the counter.The company hit financial trouble, in part because of deals it made with hedge funds that controlled warrants that could be used to buy stock at very low prices, Zannes says.Zannes left Albuquerque in 2014 for San Antonio because of the research contract with the UT Health Science Center, and she incorporated bioAffinity with the Texas Comptroller’s office in May of that year.
Classifications
AskAI Classifications
LabelsLinked Companies
